The ProFAST+ assay is a multiplex real-time RT-PCR in vitro diagnostic test that detects influenza A from nasopharyngeal swabs. It uses the same internal control and format as other FDA-cleared Prodesse tests for respiratory infectious diseases, and easily integrates into a lab existing workflow. All products have been Prodesse on automatic extraction technology that minimizes technician practical time optimized. The test results can be achieved in less than 4 hours by ProFAST+ assay, a significant improvement over culture-based methods, which can take several days to produce a result.

The ProFAST+ assay complements the Prodesse ProFlu+ assay, which has been approved by the FDA in 2008 to recognize deleted and differentiate influenza A, influenza B, and respiratory syncytial virus . Caution Regarding ForwardroFlu+ samples with H1N1 2009 as influenza A, but unlike the ProFAST+ Test, between the different can not distinguish between the different influenza A subtypes.Over SNM – Advancing Molecular Imaging and Therapy – SNM considers its the 54th Annual Meeting 2 to 6 Jun at the Washington Convention centers in Washington, DC Session themes includes for the General Meeting 2007 brain amyloid imaging, hybrid imaging, Molecular imaging comprises in clinical trials and evaluating, functional brain imaging presence of epilepsy and dementia, imaging instrumentation infected resonance imaging, lymphoma and thyroid, cardiac the molecular imaging General Nuklearmedizin, critical members of the nursing care to nuclear pharmacies and more.